Downregulated Kynurenine 3-monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association with Schizophrenia Endophenotypes

Overview

Journal Arch Gen Psychiatry

Specialty Psychiatry

Date 2011 Jul 6

PMID 21727251

Citations 85

Authors

Ikwunga Wonodi

O Colin Stine

Korrapati V Sathyasaikumar

Rosalinda C Roberts

Braxton D Mitchell

L Elliot Hong

Yasushi Kajii

Gunvant K Thaker

Robert Schwarcz

Affiliations

Soon will be listed here.

Abstract

Context: Kynurenic acid, a metabolite of the kynurenine pathway of tryptophan degradation, is an antagonist at N-methyl-d-aspartate and α7 nicotinic acetylcholine receptors and modulates glutamate, dopamine, and acetylcholine signaling. Cortical kynurenic acid concentrations are elevated in the brain and cerebrospinal fluid of schizophrenia patients. The proximal cause may be an impairment of kynurenine 3-monooxygenase (KMO), a rate-limiting enzyme at the branching point of the kynurenine pathway.

Objectives: To examine KMO messenger RNA expression and KMO enzyme activity in postmortem tissue from the frontal eye field (FEF; Brodmann area 6) obtained from schizophrenia individuals compared with healthy control individuals and to explore the relationship between KMO single-nucleotide polymorphisms and schizophrenia oculomotor endophenotypes.

Design: Case-control postmortem and clinical study.

Setting: Maryland Brain Collection, outpatient clinics.

Participants: Postmortem specimens from schizophrenia patients (n = 32) and control donors (n = 32) and a clinical sample of schizophrenia patients (n = 248) and healthy controls (n = 228).

Main Outcome Measures: Comparison of quantitative KMO messenger RNA expression and KMO enzyme activity in postmortem FEF tissue between schizophrenia patients and controls and association of KMO single-nucleotide polymorphisms with messenger RNA expression in postmortem FEF and schizophrenia and oculomotor endophenotypes (ie, smooth pursuit eye movements and oculomotor delayed response).

Results: In postmortem tissue, we found a significant and correlated reduction in KMO gene expression and KMO enzyme activity in the FEF in schizophrenia patients. In the clinical sample, KMO rs2275163 was not associated with a diagnosis of schizophrenia but showed modest effects on predictive pursuit and visuospatial working memory endophenotypes.

Conclusion: Our results provide converging lines of evidence implicating reduced KMO activity in the etiopathophysiology of schizophrenia and related neurocognitive deficits.

Citing Articles

Gene Variant Frequencies of , , , and in Substance Use Disorder Cohorts.

Contella L, Farrell C, Boccuto L, Litwin A, Snyder M Genes (Basel). 2024; 15(11).

PMID: 39596587 PMC: 11594152. DOI: 10.3390/genes15111388.

The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability.

Mercuriali G, Lodde L, Paribello P, Sapienza J, Corona A, Ave C Front Psychiatry. 2024; 15:1451678.

PMID: 39540006 PMC: 11557306. DOI: 10.3389/fpsyt.2024.1451678.

Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pocivavsek A, Schwarcz R, Erhardt S Pharmacol Rev. 2024; 76(6):978-1008.

PMID: 39304346 PMC: 11549936. DOI: 10.1124/pharmrev.124.000239.

Changes in kynurenine metabolites in the gray and white matter of the dorsolateral prefrontal cortex of individuals affected by schizophrenia.

Antenucci N, DErrico G, Fazio F, Nicoletti F, Bruno V, Battaglia G Schizophrenia (Heidelb). 2024; 10(1):27.

PMID: 38413629 PMC: 10899223. DOI: 10.1038/s41537-024-00447-3.

Developmental Exposure to Kynurenine Affects Zebrafish and Rat Behavior.

Marszalek-Grabska M, Gawel K, Kosheva N, Kocki T, Turski W Cells. 2023; 12(18).

PMID: 37759447 PMC: 10526278. DOI: 10.3390/cells12182224.

References

Aoyama N, Takahashi N, Saito S, Maeno N, Ishihara R, Ji X . Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav. 2006; 5(4):364-8. DOI: 10.1111/j.1601-183X.2006.00231.x. View

Lisman J, Coyle J, Green R, Javitt D, Benes F, Heckers S . Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008; 31(5):234-42. PMC: 2680493. DOI: 10.1016/j.tins.2008.02.005. View

Schwarcz R, Rassoulpour A, Wu H, Medoff D, Tamminga C, Roberts R . Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001; 50(7):521-30. DOI: 10.1016/s0006-3223(01)01078-2. View

Lipska B, Deep-Soboslay A, Weickert C, Hyde T, Martin C, Herman M . Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry. 2006; 60(6):650-8. DOI: 10.1016/j.biopsych.2006.06.019. View

Rosano C, Sweeney J, Melchitzky D, Lewis D . The human precentral sulcus: chemoarchitecture of a region corresponding to the frontal eye fields. Brain Res. 2003; 972(1-2):16-30. DOI: 10.1016/s0006-8993(03)02431-4. View

Fukushima K, Yamanobe T, Shinmei Y, Fukushima J . Predictive responses of periarcuate pursuit neurons to visual target motion. Exp Brain Res. 2002; 145(1):104-20. DOI: 10.1007/s00221-002-1088-7. View

Kumari V, Ettinger U, Crawford T, Zachariah E, Sharma T . Lack of association between prepulse inhibition and antisaccadic deficits in chronic schizophrenia: implications for identification of schizophrenia endophenotypes. J Psychiatr Res. 2005; 39(3):227-40. DOI: 10.1016/j.jpsychires.2004.08.007. View

Lodge D, Anis N, Burton N . Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neurosci Lett. 1982; 29(3):281-6. DOI: 10.1016/0304-3940(82)90330-5. View

Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M . Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry. 2002; 59(12):1085-96. DOI: 10.1001/archpsyc.59.12.1085. View

10.

Thaker G, Ross D, Cassady S, Adami H, Laporte D, Medoff D . Smooth pursuit eye movements to extraretinal motion signals: deficits in relatives of patients with schizophrenia. Arch Gen Psychiatry. 1998; 55(9):830-6. DOI: 10.1001/archpsyc.55.9.830. View

11.

Avila M, Adami H, McMahon R, Thaker G . Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype. Schizophr Bull. 2003; 29(2):299-309. DOI: 10.1093/oxfordjournals.schbul.a007006. View

12.

Muller N, Schwarz M . Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006; 10(2):131-48. DOI: 10.1007/BF03033242. View

13.

Gottlieb J, Macavoy M, Bruce C . Neural responses related to smooth-pursuit eye movements and their correspondence with electrically elicited smooth eye movements in the primate frontal eye field. J Neurophysiol. 1994; 72(4):1634-53. DOI: 10.1152/jn.1994.72.4.1634. View

14.

Hong L, Tagamets M, Avila M, Wonodi I, Holcomb H, Thaker G . Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol Psychiatry. 2005; 57(7):726-32. DOI: 10.1016/j.biopsych.2004.12.015. View

15.

Lewis C, Levinson D, Wise L, DeLisi L, Straub R, Hovatta I . Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003; 73(1):34-48. PMC: 1180588. DOI: 10.1086/376549. View

16.

Holzman P, PROCTOR L, Hughes D . Eye-tracking patterns in schizophrenia. Science. 1973; 181(4095):179-81. DOI: 10.1126/science.181.4095.179. View

17.

Asp L, Holtze M, Powell S, Karlsson H, Erhardt S . Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int J Neuropsychopharmacol. 2009; 13(4):475-85. PMC: 2857580. DOI: 10.1017/S1461145709990253. View

18.

Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom L, Engberg G . Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001; 313(1-2):96-8. DOI: 10.1016/s0304-3940(01)02242-x. View

19.

Leonard S, Adler L, Benhammou K, Berger R, Breese C, Drebing C . Smoking and mental illness. Pharmacol Biochem Behav. 2002; 70(4):561-70. DOI: 10.1016/s0091-3057(01)00677-3. View

20.

Louchart-de la Chapelle S, Nkam I, Houy E, Belmont A, Menard J, Roussignol A . A concordance study of three electrophysiological measures in schizophrenia. Am J Psychiatry. 2005; 162(3):466-74. DOI: 10.1176/appi.ajp.162.3.466. View